See title and evidence table for the studied intervention.,
does it really help with The stated clinical outcome in the title.?
research showsThe grade is D with 34 points. In PALLAS, the first coprimary efficacy outcome occurred in 43 dronedarone versus 19 placebo participants, HR 2.29 (95% CI 1.34 to 3.94), and the trial stopped early for increased cardiovascular events.
ads claimMarketing should stay within the studied population, intervention, comparator, endpoint, and duration.
Useful facts when choosing a product
- PALLAS stopped early because cardiovascular events increased.
- ANDROMEDA addressed a different population and primary endpoint.
Chamgap Semantic Classification Code
Candidate index · review held
M.dronedarone.UNK.MULTI.reduce.MULTIMedicinal interventions > Dronedarone > Unknown > Multiple: primary unresolved > Reduction claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
PALLAS enrolled 3,236 patients with permanent atrial fibrillation and vascular risk. Its data and safety monitoring board recommended termination because cardiovascular events increased with dronedarone. ANDROMEDA enrolled 627 recently hospitalized patients with severe systolic heart failure and had a different primary endpoint. The trials shared Camm, Alings, Blomström, and Torp-Pedersen as authors and shared Sanofi-Aventis funding.
Why this is classified as D (34)
The grade is D with 34 points. The cited primary source was checked directly; see the Korean text and evidence table for exact arm-level results.
Counterpoint. Important limitations and alternative evidence are reported in the Korean text.
Rejudgment record. Cross-check applied — PALLAS efficacy harm and safety termination, ATHENA benefit, and the distinct non-independent ANDROMEDA question
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E- | Harm increased in the trials |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Primary claim | D | The grade is D with 20 points. The cited primary source was checked directly; see the Korean text and evidence table for exact arm-level results. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Connolly SJ et al. 2011 PALLAS | Multinational double-blind placebo-controlled randomized trial | 3,236 participants | Funded by Sanofi-Aventis | Composite stroke, myocardial infarction, systemic embolism, or cardiovascular death | Dronedarone 43 versus placebo 19; HR 2.29 (95% CI 1.34-3.94) | Pivotal evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-07).
Final verification and publication gate: Codex · Evidence date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] Verdict 2407: dronedarone permanent af severe heart failure cardiovascular benefit — Evidence Grade D·34. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/dronedarone-permanent-af-severe-heart-failure-cardiovascular-benefit/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.